OLD National Bancorp IN Has $2.33 Million Stock Position in Edwards Lifesciences Corporation $EW

OLD National Bancorp IN lowered its position in Edwards Lifesciences Corporation (NYSE:EW) by 31.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,037 shares of the medical research company’s stock after selling 13,318 shares during the quarter. OLD National Bancorp IN’s holdings in Edwards Lifesciences were worth $2,325,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of EW. Brighton Jones LLC acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $266,000. NewEdge Advisors LLC increased its holdings in Edwards Lifesciences by 8.1% in the second quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock worth $2,787,000 after buying an additional 2,665 shares during the last quarter. Sei Investments Co. raised its position in Edwards Lifesciences by 16.7% during the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock valued at $32,285,000 after acquiring an additional 58,988 shares in the last quarter. Squarepoint Ops LLC lifted its stake in Edwards Lifesciences by 277.7% in the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock valued at $5,417,000 after acquiring an additional 50,924 shares during the last quarter. Finally, Treasurer of the State of North Carolina lifted its stake in Edwards Lifesciences by 0.4% in the second quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock valued at $21,028,000 after acquiring an additional 1,065 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the sale, the vice president owned 98,611 shares in the company, valued at $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $83.01, for a total transaction of $84,587.19. Following the completion of the sale, the vice president directly owned 33,934 shares in the company, valued at $2,816,861.34. This trade represents a 2.92% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 81,038 shares of company stock valued at $6,683,255 in the last ninety days. 0.31% of the stock is owned by company insiders.

Edwards Lifesciences Trading Up 1.2%

Shares of EW opened at $90.81 on Friday. The stock’s 50-day moving average price is $84.41 and its 200 day moving average price is $83.26. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $52.29 billion, a price-to-earnings ratio of 48.30, a P/E/G ratio of 2.25 and a beta of 0.87. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $92.46.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The company had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. During the same quarter last year, the company earned $0.64 EPS. The company’s quarterly revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, research analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on EW. Royal Bank Of Canada restated an “outperform” rating and set a $100.00 price target on shares of Edwards Lifesciences in a research note on Tuesday, June 16th. Evercore reiterated an “outperform” rating and issued a $93.00 price objective on shares of Edwards Lifesciences in a report on Friday, April 24th. Wolfe Research raised shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price on the stock in a research report on Wednesday, April 1st. Mizuho set a $95.00 target price on Edwards Lifesciences and gave the company an “outperform” rating in a report on Monday, April 13th. Finally, Barclays reaffirmed an “overweight” rating and issued a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $95.96.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.